Tumor Biology

, Volume 36, Issue 2, pp 669–673 | Cite as

Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients

  • Liuyu Xu
  • Qingli Zhao
  • Shengliang Huang
  • Shun Li
  • Jin Wang
  • Qing Li
Research Article

Abstract

The aim of this study was to determine whether baseline serum C-reactive protein (CRP) levels were associated with overall survival in patients with metastatic prostate cancer in the Chinese population. A total of 135 patients with metastatic prostate cancer were retrospectively reviewed. Both Kaplan-Meier product-limit method and multivariable analysis by Cox regression model were used to assess the prognostic role of serum CRP levels on overall survival of patients with metastatic prostate cancer. There were 51 patients (37.8 %) with higher values of baseline serum CRP levels (≥10 mg/L). Kaplan-Meier product-limit method and log-rank test showed that patients with high serum CRP level (≥10 mg/L) had significantly worse overall survival than those patients with normal serum CRP level (<10 mg/L) (P < 0.001). The multivariable analysis by Cox regression model further showed that high serum CRP level (≥10 mg/L) was a significantly independent predictor of overall survival (hazard ratio (HR) = 2.39; 95 % confidence interval (95 % CI) 1.56–2.39, P < 0.001). In addition, high Gleason score (≥8) also was an independent predictor of overall survival (HR = 1.80; 95 % CI 1.16–2.79, P = 0.008). In conclusion, serum CRP level is useful to predict the prognosis of metastatic prostate cancer patients, and high serum CRP level is a significantly independent predictor of worse overall survival.

Keywords

Prostate cancer C-reactive protein Overall survival 

Notes

Conflicts of interest

None

References

  1. 1.
    de Resende MF, Chinen LT, Vieira S, Jampietro J, da Fonseca FP, Vassallo J, et al. Erratum to: prognostication of OCT4 isoform expression in prostate cancer. Tumor Biol. 2014;34(5):2665–73.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology (Williston Park). 2014;28(2):135–42.Google Scholar
  4. 4.
    Wang HT, Li BG, Zhang PY, Yao YH, Chang JW. Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumor Biol. 2014;35(1):595–601.CrossRefGoogle Scholar
  5. 5.
    Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014;83(3):592–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer. 2013;108(10):1925–30.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chao C, Chi M, Preciado M, Black MH. Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control. 2013;24(9):1615–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013;3(8):849–61.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30(1):677–706.CrossRefPubMedGoogle Scholar
  10. 10.
    Kowalewska M, Nowak R, Chechlinska M. Implications of cancer-associated systemic inflammation for biomarker studies. Biochim Biophys Acta. 2010;1806(2):163–71.PubMedGoogle Scholar
  11. 11.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6.CrossRefPubMedGoogle Scholar
  12. 12.
    McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Salazar J, Martinez MS, Chavez M, Toledo A, Anez R, Torres Y, et al. C-reactive protein: clinical and epidemiological perspectives. Cardiol Res Pract. 2014;2014(1):605810.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013;56(1):131–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers. 2011;26(4):209–15.PubMedGoogle Scholar
  17. 17.
    Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol. 2013;20(2):161–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brucher B, et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer. 2014;5(1):3–24.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Emadi Bayqi M, Soheili ZS, Essmann F, Deezaqi A, Engers R, Goering W, et al. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumor Biol. 2010;31(4):297–307.CrossRefGoogle Scholar
  20. 20.
    Hausmann S, Kong B, Michalski C, Erkan M, Friess H. The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 2014;816(1):129–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Nowarski R, Gagliani N, Huber S, Flavell RA. Innate immune cells in inflammation and cancer. Cancer Immunol Res. 2013;1(2):77–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Al Ghazal A, Steffens S, Steinestel J, Lehmann R, Schnoeller TJ, Schulte-Hostede A, et al. Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer. BMC Urol. 2013;13(1):53.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One. 2013;8(10):e76779.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    De Luca A, de Gaetano DK, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, et al. The association of high-sensitivity C-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis. 2013;13(1):414.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PLoS One. 2013;8(7):e69232.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Saito K, Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther. 2010;10(12):1979–89.CrossRefPubMedGoogle Scholar
  27. 27.
    Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer: results of a pilot study. Tumor Biol. 2012;33(5):1695–700.CrossRefGoogle Scholar
  28. 28.
    Xia WX, Ye YF, Lu X, Wang L, Ke LR, Zhang HB, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS One. 2013;8(10):e76958.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    El-Shater Bosaily A, Arya M, Ahmed H. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013;119(22):4052–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014;32(5):707–13.CrossRefPubMedGoogle Scholar
  31. 31.
    Cui DW, Cheng YJ, Jing SW, Sun GG. Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell. Tumor Biol. 2014;35(4):3017–24.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Liuyu Xu
    • 1
  • Qingli Zhao
    • 1
  • Shengliang Huang
    • 1
  • Shun Li
    • 1
  • Jin Wang
    • 1
  • Qing Li
    • 1
  1. 1.Department of Urology, Shandong Provincial Qianfoshan HospitalShandong UniversityJinanChina

Personalised recommendations